TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis

He, Guangzhi; Zheng, Chenhong; Huo, Hui-ping; Zhang, Huiming; Zhu, Zhiquan; Li, Junlai; Zhang, Hongpeng

doi:10.1016/j.intimp.2016.09.015

Cited by 13 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, a significant benefit in OS was confirmed regardless of subgroup composition, and more intriguingly, our analysis indicated that short-term recurrence was intensely reduced with immunotherapy independent of the heterogeneity. The clinical benefit of the combined immunotherapy with DCs and CIKs has been demonstrated in many clinical studies[17,44]. This combined approach was reported to have greater antitumor activity in vitro than CIK treatment alone[45], while our analysis failed to find sufficient clinical data to support it.…”

Section: Discussionmentioning

confidence: 66%

“…CIKs harbor high capacity of proliferation and have a cytolytic effect against cancer cells. Although several analyses have supported the beneficial effect of cellular immunotherapy when combined with specific HCC treatment[16,17], the efficacy and necessity of cellular immunotherapy after different interventional therapy remains to be interrogated. In this study, a systematic review and meta-analysis was performed to investigate the efficacy of cellular immunotherapy, involving DCs, CIKs and DC/CIK combination therapy, combined with different treatments of HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis

Cao

Kong

Liu

et al. 2019

WJG

View full text Add to dashboard Cite

BACKGROUND Hepatocellular carcinoma (HCC) has been revealed as the second most common cause of cancer-related deaths worldwide. The introduction of cell-based immunotherapy, including dendritic cells (DCs) and cytokine-induced killer cells (CIKs), has brought HCC patients an effective benefit. However, the efficacy and necessity of cellular immunotherapy after different interventional therapy remains to be further explored. AIM To investigate the efficacy of cellular immunotherapy, involving DCs and CIKs, combined with different conventional treatments of HCC. METHODS We performed a literature search on PubMed and Web of Science up to February 15, 2019. Long-term efficacy (overall survival and recurrence) and short-term adverse effects were investigated to assess the effectiveness of immunotherapy with DCs and/or CIKs. Review Manager 5.3 was used to perform the analysis. RESULTS A total of 22 studies involving 3756 patients selected by eligibility inclusion criteria were forwarded for meta-analysis. Combined with the conventional clinical treatment, immunotherapy with DCs and/or CIKs was demonstrated to significantly improve overall survival at 6 mo [risk ratio (RR) = 1.07; 95% confidence interval (CI): 1.01-1.13, P = 0.02], 1 year (RR = 1.12; 95%CI: 1.07-1.17, P < 0.00001), 3 years (RR = 1.23; 95%CI: 1.15-1.31, P < 0.00001) and 5 years (RR = 1.26; 95%CI: 1.15-1.37, P < 0.00001). Recurrence rate was significantly reduced by cellular immunotherapy at 6 mo (RR = 0.50; 95%CI: 0.36-0.69, P < 0.0001) and 1 year (RR = 0.82; 95%CI: 0.75-0.89, P < 0.00001). Adverse effect assessment addressed that immunotherapy with DCs and/or CIKs was accepted as a safe, feasible treatment. CONCLUSION Combination immunotherapy with DCs, CIKs and DC/CIK with various routine treatments for HCC was evidently suggested to improve patients’ prognosis by increasing overall survival and reducing cancer recurrence.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis

Cao

Kong

Liu

et al. 2019

WJG

View full text Add to dashboard Cite

show abstract

“…Multiple meta-analyses have suggested that AIT is safe and effective in reducing mortality and tumor recurrence for patients with HCC after curative therapies 213,214 or palliative therapies. [215][216][217][218][219] However, studies from India on AIT are lacking.…”

Section: Ii-2 Strongmentioning

confidence: 99%

2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations

Kumar

Acharya

Singh

et al. 2020

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management

show abstract

“…In 2016, He et al [42] published a systematic review to investigate the efficacy of immunotherapy which includes dendritic cells and cytokine-induced killer cells (DC-CIK) in combination with TACE in HCC patients. The overall analysis showed that TACE plus DC-CIK immunotherapy can improve half-year, 1-year, and 2-year median OS and PFS in HCC patients compared to TACE alone.…”

Section: Gastrointestinal Tumorsmentioning

confidence: 99%

Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy

Garofano

Gonzalez‐Carmona

Skowasch

et al. 2019

IJMS

View full text Add to dashboard Cite

Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs.

show abstract

TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis

Cited by 13 publications

References 26 publications

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis

Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis

2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations

Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy

Contact Info

Product

Resources

About